Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Zinzani, Pier Luigi, Ribrag, Vincent, Moskowitz, Craig H., Michot, Jean-Marie, Kuruvilla, John, Balakumaran, Arun, Zhang, Yayan, Chlosta, Sabine, Shipp, Margaret A., Armand, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5766837/
https://ncbi.nlm.nih.gov/pubmed/28490569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-12-758383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados